Market Pathways Scorecard: Q1 FDA Authorizations
A graphical look at FDA novel device approvals, 510(k)s, and PMA supplements during the first quarter of 2026.
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
A graphical look at FDA novel device approvals, 510(k)s, and PMA supplements during the first quarter of 2026.
Medtech veterans Ken Nelson and Daniel O’Mahony describe the common reasons medtech start-ups fail before reaching profitability or a successful exit.
The European Union’s AI Act retains device mandates. Excerpted from Pathways’ Picks May 13: Makary Exits FDA, EU AI Act Reforms Disappoint, UK Seeks Input, and More.